Efficacy Of Pramipexole In Parkinson’s Diesase: A Meta-analysis

Objective: In comparative trials a meta-analysis was performed to comparethe efficacy and adverse events of pramipexole and placebo as reported in thepeer-reviewed medical literature.Methods: draft the inclusion and exclusion criteria,then search randomizedcontrol trials(RCTs) on Parkinson’s disease treated withpramipexole．Computerised databases (including Cochrane Central Registerof Controlled Trials (CENTRAL),Medline,PubMed,,and Chinese NationalKnowledge Infrastructure database (CNKI)) were used to identify pertinentarticles for inclusion in this study.Two investigators independently assessedthe quality and extracted the data for the meta-analysis by the RevMan5.0.Results: eight randomized control trials were included.the total number of920in pramipexole and722in placebo.The results showed there is an obviousdecreaes of endpoints (UPDRS total,UPRRS II and UPDRSIII),and increaseof endpoints(responsder rate of theUPDRS total,UPRRS II and UPDRSIII).themeta-analysis of adverse events of pramipexole compared to placeboindicated OR>1and p<0.05for dyskinesia, fatigue, nausea, hallucination,insomnia,somnolence,constipation, which meant the use of pramipexole mayinduce these adverse events，howere，there were no evidence can improvethe use of pramipexole may induce peripheral edema,confusion,posturalhypotension,anorexia,dizziness and headache.Conclusion: pramipexole is effective in the treatment of patients withParkinson’s disease in the field of total,ADL and motor,but the Incidence ofdyskinesia，fatigue，nausea，hallucination，insomnia，somnolence，constipationwere also incerase,how to make it effetive and safety will be the further studyin the future.